Shanghai Rightongene Biotechnology Co Ltd (688217)

25.78 -0.07 (-0.27%)
Delayed Data CNY Disclaimer

Shanghai Rightongene Biotechnology Co Ltd Company Profile

Sector
Healthcare
Employees
503
Equity Type
ORD
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. It also provides molecular diagnostic reagents, and scientific research and testing services for blood diseases, solid tumors, and infectious diseases. The company was founded in 2012 and is based in Shanghai, China.
Contact Information
Address
Fengxian District Shanghai,201403 China
Phone
86 21 3328 2601
Fax
86 21 3719 9015
Top Executives
Name
Age
Since
Title
Yunhang Li 35 2019 Chairman of the Supervisory Board
Shangxian Gao 66 2018 Director
Jie Shen 36 2020 Member of the Supervisory Board
Weijian Xu 52 2018 Independent Director
Yanbo Sun 37 2022 Director
Xuewei Yuan 52 2018 Independent Director
Kejia Li 34 2021 Supervisor
Guiying Zhao 70 2018 Independent Director
Min Xu 49 2021 Director
Jun Xiong 48 2018 Deputy GM & Director
Hui Xiong 52 2018 Chairman & GM of Core Technology Personnel
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles